$ASMB
Assembly Biosciences Inc

2020 Q2 Form 10-Q Financial Statement

#000156459020036859 Filed on August 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $39.38M $3.080M $3.885M
YoY Change 1178.44% -4.28% 8.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.470M $4.080M $9.520M
YoY Change 132.11% -67.46% 67.02%
% of Gross Profit
Research & Development $23.33M $18.70M $22.70M
YoY Change 24.74% 4.82% 56.14%
% of Gross Profit
Depreciation & Amortization $100.0K $100.0K $135.0K
YoY Change 0.0% 0.0% -19.64%
% of Gross Profit
Operating Expenses $32.80M $22.78M $32.22M
YoY Change 43.97% -25.03% 59.22%
Operating Profit $6.579M -$19.70M -$28.34M
YoY Change -133.4% -27.48% 69.96%
Interest Expense $690.0K $1.180M $1.280M
YoY Change -41.53% 257.58% 204.76%
% of Operating Profit 10.49%
Other Income/Expense, Net $691.0K $1.186M $1.277M
YoY Change -41.74% 263.8% 201.89%
Pretax Income $7.270M -$18.51M -$27.06M
YoY Change -139.27% -31.02% 66.53%
Income Tax $0.00 -$11.00K -$7.000K
% Of Pretax Income 0.0%
Net Earnings $7.270M -$18.50M -$27.05M
YoY Change -139.29% -30.97% 66.48%
Net Earnings / Revenue 18.46% -600.75% -696.32%
Basic Earnings Per Share $0.21 -$0.72 -$1.05
Diluted Earnings Per Share $0.19 -$0.72 -$1.05
COMMON SHARES
Basic Shares Outstanding 35.31M 25.74M 25.54M
Diluted Shares Outstanding 37.29M 25.74M 25.67B

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $226.7M $173.8M $193.5M
YoY Change 30.44% 87.49% 77.2%
Cash & Equivalents $96.71M $34.26M $29.11M
Short-Term Investments $130.0M $139.6M $164.4M
Other Short-Term Assets $5.100M $6.700M $4.300M
YoY Change -23.88% 148.15% 138.89%
Inventory
Prepaid Expenses
Receivables $3.300M $2.903M $2.987M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $235.1M $183.5M $200.8M
YoY Change 28.15% 88.11% 77.39%
LONG-TERM ASSETS
Property, Plant & Equipment $2.063M $2.048M $2.079M
YoY Change 0.73% 220.05% 197.0%
Goodwill $12.64M $12.64M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.200M $1.693M $1.661M
YoY Change 207.15%
Total Long-Term Assets $59.70M $58.05M $58.44M
YoY Change 2.84% 29.32% 36.54%
TOTAL ASSETS
Total Short-Term Assets $235.1M $183.5M $200.8M
Total Long-Term Assets $59.70M $58.05M $58.44M
Total Assets $294.8M $241.5M $259.2M
YoY Change 22.06% 69.58% 66.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.600M $3.400M $2.400M
YoY Change 5.88% 36.0% 0.0%
Accrued Expenses $6.019M $7.585M $10.14M
YoY Change -20.65% 49.32% 120.46%
Deferred Revenue $39.66M
YoY Change -9.01%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.27M $19.94M $25.21M
YoY Change -13.36% 51.82% 106.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.900M $43.60M $40.40M
YoY Change -81.88% 14.44% 2.8%
Total Long-Term Liabilities $7.900M $43.60M $40.40M
YoY Change -81.88% 8.49% 2.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.27M $19.94M $25.21M
Total Long-Term Liabilities $7.900M $43.60M $40.40M
Total Liabilities $27.69M $66.80M $68.85M
YoY Change -58.56% 25.29% 28.44%
SHAREHOLDERS EQUITY
Retained Earnings -$458.8M -$387.3M -$368.8M
YoY Change 18.45% 31.71%
Common Stock $725.8M $26.00K $26.00K
YoY Change 2791503.85% 26.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $267.1M $174.7M $190.4M
YoY Change
Total Liabilities & Shareholders Equity $294.8M $241.5M $259.2M
YoY Change 22.07% 69.58% 66.18%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income $7.270M -$18.50M -$27.05M
YoY Change -139.29% -30.97% 66.48%
Depreciation, Depletion And Amortization $100.0K $100.0K $135.0K
YoY Change 0.0% 0.0% -19.64%
Cash From Operating Activities -$23.11M -$21.00M -$23.94M
YoY Change 10.05% 30.84% 54.45%
INVESTING ACTIVITIES
Capital Expenditures -$400.0K -$50.00K $1.488M
YoY Change 700.0% 0.0% 3715.38%
Acquisitions
YoY Change
Other Investing Activities $76.95M $25.50M $12.92M
YoY Change 201.76% 1588.74% -1318.87%
Cash From Investing Activities $76.55M $25.45M $11.44M
YoY Change 200.79% 1643.15% -1139.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $100.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 950.0K 710.0K 140.0K
YoY Change 33.8% -61.62% -90.63%
NET CHANGE
Cash From Operating Activities -23.11M -21.00M -23.94M
Cash From Investing Activities 76.55M 25.45M 11.44M
Cash From Financing Activities 950.0K 710.0K 140.0K
Net Change In Cash 54.39M 5.160M -12.36M
YoY Change 954.07% -140.5% -18.15%
FREE CASH FLOW
Cash From Operating Activities -$23.11M -$21.00M -$23.94M
Capital Expenditures -$400.0K -$50.00K $1.488M
Free Cash Flow -$22.71M -$20.95M -$25.43M
YoY Change 8.4% 30.94% 63.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9470000
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-458806000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23327000
us-gaap Operating Expenses
OperatingExpenses
55002000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
6579000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-11000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
7270000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
190000
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.77
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35307669
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25740500
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35229570
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25690617
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.19
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Net Income Loss
NetIncomeLoss
-45555000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18514000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-18503000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
32797000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41405000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4080000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18199000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6966000
CY2020Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2531000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18700000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
32000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-439421000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9082000
CY2019Q4 us-gaap Liabilities
Liabilities
66690000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17271000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3250000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
22780000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
30637000
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2531000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46373000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32558307
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
712807000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
273217000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
339907000
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3080000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
43457000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13597000
us-gaap Operating Expenses
OperatingExpenses
64572000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-201000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32558307
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
267115000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7884000
CY2020Q2 us-gaap Liabilities
Liabilities
27686000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32807519
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32807519
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
33000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
725784000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
294801000
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
104000
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
39376000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7270000
CY2019Q2 us-gaap Interest Income Other
InterestIncomeOther
1186000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
691000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21115000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19700000
CY2019Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
79000
CY2019Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
7000
CY2019Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
269889000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1730000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1186000
CY2019Q4 asmb Proceeds From Sale Of Pre Funded Warrants
ProceedsFromSaleOfPreFundedWarrants
37500000
CY2020Q2 us-gaap Interest Income Other
InterestIncomeOther
691000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
251768000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45395000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
237000
us-gaap Share Based Compensation
ShareBasedCompensation
12058000
asmb Noncash Rent Expense
NoncashRentExpense
2308000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-59000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-304000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2155000
asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2247000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48334000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
470000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
44240000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
119252000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
22700000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
97242000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
49977000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41471000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
96709000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
174707000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.77
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37291474
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25740500
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35229570
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25690617
us-gaap Net Income Loss
NetIncomeLoss
-19385000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
331000
asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
467000
asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
515000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1069000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
846000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7213000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46732000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34258000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
260000
us-gaap Share Based Compensation
ShareBasedCompensation
8645000
asmb Accretion And Amortization Of Investments In Marketable Debt Securities
AccretionAndAmortizationOfInvestmentsInMarketableDebtSecurities
101000
asmb Accretion And Amortization Of Investments In Marketable Debt Securities
AccretionAndAmortizationOfInvestmentsInMarketableDebtSecurities
1141000
asmb Noncash Rent Expense
NoncashRentExpense
2208000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-18000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-102000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
5000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
473000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5068000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1655000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
516000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-279000
asmb Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
-464000
asmb Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
248000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2416000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2428000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-37048000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-996000
asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2099000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44944000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1539000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
93667000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
131591000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
36885000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
602000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
545000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
14225000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
483000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
467000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
190000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6937000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
7270000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
267115000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
190401000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
191000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
515000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
52000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2051000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-18503000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
273217000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
602000
us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
467000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
305000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11909000
us-gaap Net Income Loss
NetIncomeLoss
-19385000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
267115000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
210653000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
331000
us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
515000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
-4000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
160000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8607000
us-gaap Net Income Loss
NetIncomeLoss
-45555000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
174707000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
asmb Number Of Approved Products
NumberOfApprovedProducts
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include revenue recognition, clinical trial accruals, recoverability and useful lives (indefinite or finite) of intangible assets, assessment of impairment of goodwill, provisions for income taxes, amounts receivable and recognized as revenue under the Allergan Collaboration Agreement, measurement of operating lease liabilities, and the fair value of stock options, stock appreciation rights, and restricted stock units (RSUs) granted to employees, directors and consultants.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ materially from those estimates and assumptions.</p>
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
7270000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-18503000
us-gaap Net Income Loss
NetIncomeLoss
-19385000
us-gaap Net Income Loss
NetIncomeLoss
-45555000
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35307669
CY2020Q2 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2019Q4 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3073000
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25740500
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35229570
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25690617
CY2020Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1983805
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37291474
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25740500
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35229570
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25690617
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.77
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.19
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.77
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3587827
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5715064
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7655242
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5715064
CY2020Q2 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
224120000
CY2020Q2 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
409000
CY2020Q2 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
224529000
CY2019Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
269817000
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3030000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1437000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1200000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2063000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1830000
CY2020Q2 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
200000
CY2019Q2 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
300000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4186000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5312000
CY2020Q2 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
1019000
CY2019Q4 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
2094000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
814000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
880000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6019000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8286000
CY2019Q4 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
2100000
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 asmb Initial Public Offering Value Of Shares Authorized
InitialPublicOfferingValueOfSharesAuthorized
250000000.0
CY2020Q2 asmb Common Stock Remaining Shares Available For Sale
CommonStockRemainingSharesAvailableForSale
21400000
asmb Warrants Exercisable Description
WarrantsExercisableDescription
under their terms, the outstanding pre-funded warrants to purchase shares of the Company’s common stock generally may not be exercised if the holder’s ownership of the Company’s common stock would exceed 19.99% following such exercise.
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2439538
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2439538
CY2020Q2 asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2019Q2 asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
0
asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
0
asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1900000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3000000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
4600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000000.0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
700000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12058000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8645000
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
32200000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7134000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2068000
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3300000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3400000
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
408000
CY2019Q2 us-gaap Variable Lease Cost
VariableLeaseCost
300000
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
137000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
37048000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
996000
CY2020Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
us-gaap Short Term Lease Cost
ShortTermLeaseCost
200000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
433000
CY2019Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
37048000
asmb Contract With Customer Liability In Additions
ContractWithCustomerLiabilityInAdditions
0
asmb Contract With Customer Liability In Deduction
ContractWithCustomerLiabilityInDeduction
37048000
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
40660000
asmb Contract With Customer Liability In Additions
ContractWithCustomerLiabilityInAdditions
0
asmb Contract With Customer Liability In Deduction
ContractWithCustomerLiabilityInDeduction
996000
CY2019Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
39664000
CY2020Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
36041000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2020Q2 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
800000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11100000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10800000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1158000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1117000
us-gaap Operating Lease Cost
OperatingLeaseCost
2308000
us-gaap Operating Lease Cost
OperatingLeaseCost
2208000
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
100000
CY2019Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
112000
us-gaap Variable Lease Cost
VariableLeaseCost
692000
us-gaap Variable Lease Cost
VariableLeaseCost
599000
CY2020Q2 us-gaap Lease Cost
LeaseCost
1666000
CY2019Q2 us-gaap Lease Cost
LeaseCost
1529000
us-gaap Lease Cost
LeaseCost
3200000
us-gaap Lease Cost
LeaseCost
3240000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
545000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3991000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3627000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3325000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
13299000
us-gaap Operating Lease Payments
OperatingLeasePayments
2247000
us-gaap Operating Lease Payments
OperatingLeasePayments
2099000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
14225000
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M12D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.095
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.094
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2356000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2165000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11134000

Files In Submission

Name View Source Status
0001564590-20-036859-index-headers.html Edgar Link pending
0001564590-20-036859-index.html Edgar Link pending
0001564590-20-036859.txt Edgar Link pending
0001564590-20-036859-xbrl.zip Edgar Link pending
asmb-10q_20200630.htm Edgar Link pending
asmb-10q_20200630_htm.xml Edgar Link completed
asmb-20200630.xsd Edgar Link pending
asmb-20200630_cal.xml Edgar Link unprocessable
asmb-20200630_def.xml Edgar Link unprocessable
asmb-20200630_lab.xml Edgar Link unprocessable
asmb-20200630_pre.xml Edgar Link unprocessable
asmb-ex311_13.htm Edgar Link pending
asmb-ex312_10.htm Edgar Link pending
asmb-ex321_15.htm Edgar Link pending
asmb-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending